Suchergebnisse
Katalog
Mehr
Suchmaske
Suchergebnisse einschränken oder erweitern
Aktive Suchfilter
Weniger Treffer
Art der Quelle
Thema
- biotechnology 2 Treffer
- bladder cancer 2 Treffer
- cancer 2 Treffer
- clinical research 2 Treffer
- drugs and therapies 2 Treffer
-
22 weitere Werte:
- fda 2 Treffer
- non-muscle invasive bladder cancer 2 Treffer
- oncology 2 Treffer
- pharmaceuticals 2 Treffer
- post-trial research 2 Treffer
- technology 2 Treffer
- therapeutics 2 Treffer
- transurethral resection of bladder 2 Treffer
- u.s. food and drug administration 2 Treffer
- adrenal cortex hormones 1 Treffer
- adrenocortical hormones 1 Treffer
- drug approval 1 Treffer
- duchenne muscular dystrophy 1 Treffer
- fda actions 1 Treffer
- genetic diseases and conditions 1 Treffer
- glucocorticoids 1 Treffer
- pharmaceutical chemistry 1 Treffer
- pharmaceutical sciences 1 Treffer
- ractigen therapeutics 1 Treffer
- research personnel 1 Treffer
- state university of new york at binghamton 1 Treffer
- therapeutic use of proteins 1 Treffer
Sprache
Inhaltsanbieter
3 Treffer
-
Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy.In: Medical Letter on the CDC & FDA, 2024-06-03, S. 34-34serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2024-05-10, S. 26-26serialPeriodicalZugriff:
-
In: Medical Letter on the CDC & FDA, 2023-11-14, S. 518-518serialPeriodicalZugriff: